Clinical Trial Search

Primary: Cumulative Number of New Gadolinium-enhancing (GdE) T1 Lesions at Week 12 — 4.2; 1.7; 2.2; 2.2 Cumulative number of lesions — p=<0.001

Primary: Postdose Strain-specific Hemagglutination-inhibition (HAI) Antibody Geometric Mean Fold Rise From Week 8 to Week 12 — 3.60; 3.13; 3.25; 3.85 Fold change

Primary: Image Quality of the CT Scans Using Different Contrast Agents — 333; 357; 362; 288 hounsfield units

Primary: Double-blind MP: Change From Baseline in JRS Severity Subscore at Day 43 (Visit 4) — -0.6; -1.0; -1.8 score on a scale — p==0.0004

Primary: Caregiver Transfer Efficacy — 76.41; 79.57; 64.44; 67.17 units on a scale — p=0.973

Primary: Number of Participants With Adrenal Insufficiency — 2; 1 Participants

Primary: Number of Responder Patients (Structural Remodelling) — 94 Participants

Primary: Change of Beck Depression Inventory-II Scores Over 16 Weeks — 18.82; 17.50; 22.68; 22.03 units on a scale — p=<0.05

Primary: Percentage of Participants With a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90) From Baseline — 42.2; 72.8 percentage of participants — p=<0.001

Primary: Change in the Corrected QT-interval During Nocturnal Hypoglycemia — 3; 5 Participants

Primary: PCL-5 (Post Traumatic Stress Disorder Checklist for the Diagnostic and Statistical Manual of Mental Disorders) for Use in Treating PTSD Symptoms — 44.25 scores on a scale

Primary: Difference in Circumferential Measurement Related to Sham and Therapeutic Group at 12 Weeks Post-treatment — 1.9; 0 cm

Primary: Change in sCD14 From Baseline to Week 24 — 35.75; -251.40; -101.75 pg/mL

Primary: Posttraumatic Stress Disorder (PTSD) Symptoms as Measured by the Clinician Administered Posttraumatic Stress Disorder Scale (CAPS) — 41.7; 43.3; 51.5 Scores on a scale

Primary: Number of Participants With BK Viral Load <600 Copies/mL — 13; 17 Participants